Article
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
Cancer research - 15 May 2020
Starrett Jacqueline H, Guernet Alexis A, Cuomo Maria Emanuela, Poels Kamrine E, van Alderwerelt van Rosenburgh Iris K, Nagelberg Amy, Farnsworth Dylan, Price Kristin S, Khan Hina, Ashtekar Kumar Dilip, Gaefele Mmaserame, Ayeni Deborah, Stewart Tyler F, Kuhlmann Alexandra, Kaech Susan M, Unni Arun M, Homer Robert, Lockwood William W, Michor Franziska, Goldberg Sarah B, Lemmon Mark A, Smith Paul D, Cross Darren A E, Politi Katerina
Abstract excerpt
Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging as the preferred first-line therapy for EGFR-mutant lung cancer, yet resistance inevitably develops in patients. We modeled acquired resistance to osimertinib in transgenic mouse models of EGFRL858R -induced lung adenocarcinoma and found that it is mediated largely through secondary mutations in EGFR-either C797S or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.